ACHL News and Press, Achilles Therapeutics plc From 08/31/23

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-04 13:33:19 ET Achilles Therapeutics press release ( NASDAQ: ACHL ): Q2 GAAP EPS of -$0.42 misses by $0.02 . Cash and cash equivalents were $143.7 million as of June 30, 2023, as compared to $173.3 million as of December 31, 2022. The Company anticipates t...

- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - -   neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell...

2023-05-21 10:03:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such...

2023-05-10 13:31:16 ET Achilles Therapeutics press release ( NASDAQ: ACHL ): Q1 GAAP EPS of -$0.44. Strong cash position of $158.5 million supports operations into mid-2025 Cash and cash equivalents: Cash and cash equivalents were $158.5 million as of March 31, 2023, a...

- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5 million supports operations into mid-2025 - LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles...

LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company’s new AI application, trained ...

2023-04-26 02:48:52 ET Clinical-stage biopharmaceutical company, Achilles Therapeutics ( ACHL ) r eceives Nasdaq notice as it is not in compliance with the $1.00 minimum bid price requirement of the ADS. The company has 180 days, or until October 18, 2023 to regain compli...

LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 f...

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor - - Patent applies to any modality, including vaccine and autologous T cell therapy - LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles The...